Akshaya Bio Inc.

January 22, 2018 | Author: Anonymous | Category: Science, Health Science, Immunology
Share Embed Donate


Short Description

Download Akshaya Bio Inc....

Description

Akshaya Bio Inc. Chimigen® Technology-Based Molecular Vaccines

InnovationScan

November, 2013 Akshaya Bio Inc.

…..…………..focus is on vaccines

1

Akshaya Bio Inc. Outline • The Company Management Research Team Collaborators

• Chimigen® Platform Technology Unique Features Product Pipeline Status • Highlights • Contacts Akshaya Bio Inc.

…..…………..focus is on vaccines

2

Akshaya Bio Inc.- Current • Based in Edmonton, Alberta  8223 Roper Road  Currently a team of Nine, Eight Researchers (7 Ph.Ds, 1 B.Sc. 1 MBA)

• Founded in 2010  Dendritic cell receptor-targeted vaccines  Proprietary technology • 16 issued patents • 32 patents pending worldwide  Acquired Chimigen® Technology from Paladin Labs Inc. and ViRexx Medical Corp., (TSX, AMEX)

• External Partners in Research and Development  NRC-IRAP, CHTD, AITF, Gates Foundation

• Unique technology platform  Improved antigen presentation

• Rich Product Pipeline  HBV, HCV, HIV, Cancer, Malaria, Biodefense, Influenza, Akshaya Bio Inc.

…..…………..focus is on vaccines

3

Management Team • Satish Chandran, Ph.D • Chief Executive Officer • Rajan George, M.Sc, Ph.D • President and Chief Scientific Officer • Bruce Hirsche, QC • General & Intellectual Property Counsel • Rohit George, BA, MBA • Business Operations Akshaya Bio Inc.

…..…………..focus is on vaccines

4

Research Team • Allan Ma, Ph.D • Senior Scientist, Virologist • Dakun Wang, Ph.D • Senior Scientist, Immunologist • Yun Xia, Ph.D • Cell Biologist/Immunologist • Morris Kostiuk, Ph.D • Biochemist/Molecular Biologist • Gina Thede, Ph.D • Biochemist/Molecular Biologist • Hue Anh Luu, B.Sc • Technologist Akshaya Bio Inc.

…..…………..focus is on vaccines

5

Collaborators •





• • • • •

NRC/IRAP – Eric Swanson, Ph.D Nuron Biotech – HBV Vaccine License – HCV Vaccine License Option University of Alberta- HBV & HCV Clinical Research – Klaus Gutfreund, M.D, Assoc. Professor, Medicine, U of A – Mang Ma, M.D, Assoc. Professor, Medicine, U of A VIDO/InterVac-Immunology in Animals – Qiang Li, Ph.D NRC-NINT-Nanoparticles – Nils Peterson, Ph.D CHTD/Gates Foundation DRDC Suffield – Les Nagata, Ph.D (Head Biotechnology Section) NIH – HBV & HCV

Akshaya Bio Inc.

…..…………..focus is on vaccines

6

Chimigen® Platform Technology

Novel Approach to an Established Concept

Dendritic Cell Receptor-Targeted Vaccines

Akshaya Bio Inc.

…..…………..focus is on vaccines

7

Chimigen®- A Platform Technology Chimigen® Recombinant Molecule 6xHis

6xHis Antigen

Antigen

CHO

IRD CHO

Peptide Linker Portion of CH 1

S-S

Hinge Region

S-S S S

CHO

CH2 S S CCH2 H2

Xenotypic (Murine) Fc

CHO

TBD

SS SS

C H3

CH3

Peptide

Strong Intellectual Property Position 16 Issued Patents, 32 Patent Applications Pending worldwide Akshaya Bio Inc.

…..…………..focus is on vaccines

8

Chimigen®- A Platform Technology • Characteristics of both Antigen (Ag) and Antibody (Ab) • Xenotypic (foreign) Ab fragment makes whole molecule “foreign” & thus more immunogenic • Adaptable platform – Adaptable to disease-specific multiple molecular antigenic epitopes – HBV, HCV, HIV, Biodefense Applications (Alphaviruses), Pandemic Preparedness (H5N1, H1N1), Malaria, Cancer etc.

• Designed to generate broad immune responses – Cellular (Class I)- critical to clear virus infected & cancer cells – Humoral (Class II)- Antibodies

• Potential use for both Prophylactic & Therapeutic Vaccines Akshaya Bio Inc.

…..…………..focus is on vaccines

9

Chimigen®- A Platform Technology •





• •

Effective at low doses (µg) – Targets multiple cell types relevant to immune activation – Targets multiple specific receptors on Antigen Presenting Cells • Dendritic Cells (Fcy, Lectin Receptors) Minimal safety concerns – Utilizes classical antigen presentation pathway – No added adjuvant • Eliminates many adverse events • Eliminates T cell sequestration, dysfunction & deletion (Nat. Med. 2013, Lu. et al) Ease of production and scalability – Utilizes insect cell-based production • Increased antigenicity through production of the chimeric molecule in Insect Cells • Imparts non-mammalian glycosolation; Highly immunogenic Established purification systems Binding and uptake through Fc and Lectin receptors

Akshaya Bio Inc.

…..…………..focus is on vaccines

10

Product Pipeline & Status • HBV Therapeutic/Prophylactic Vaccine • Preclinical completed (Licensed to Nuron, co-development)

• HCV Therapeutic/Prophylactic Vaccine • Preclinical (Nuron co-development, option to license)

• HIV Prophylactic/Therapeutic Vaccine • Discovery (CHTD-NRC-IRAP)

• Cancer Vaccine • Discovery

• Malaria • Late discovery stage (Gates Foundation); ready for animal studies

• Biodefense and Pandemic Applications • Alphavirus (WEEV) Vaccine, Discovery/Preclinical

• Influenza H5 & H1 • Pre-clinical

Akshaya Bio Inc.

…..…………..focus is on vaccines

11

Akshaya’s Competitive Advantages • Meets major unmet needs  No vaccine/therapy available • Efficacy, it works  Proof of Concept established  HBV Chronic Carriers  Breaking Tolerance • No Adjuvant  Eliminates majority of the adverse reactions  The Scare Factor  Eliminates production of “dysfunctional CTLs” • Re-educating the immune system  Uses Dendritic Cell Receptor  Natural endogenous process for uptake and presentation of antigens & induction of broad immune responses

Akshaya Bio Inc.

…..…………..focus is on vaccines

12

Chimigen® Vaccine Highlights Highlights • Versatile, Adaptable Platform • Dendritic Cell Receptor-Targeted Vaccines • Generates broad immune responses – Cellular (Class I)- critical to clear virus infected & cancer cells – Humoral (Class II)- Abs- Helps CTLs • Proof of principle established with Chimigen® HBV Therapeutic Vaccine • Potential use for both Prophylactic & Therapeutic Vaccines • Strong Intellectual Property Position Akshaya Bio Inc.

…..…………..focus is on vaccines

13

Contacts • Satish Chandran, Ph.D

Rajan George, M.Sc, Ph.D



Chief Executive Officer

President & Chief Scientific Officer

• • • •

8223 Roper Road Edmonton Alberta, T6E 6S4 Canada

8223 Roper Road Edmonton Alberta, T6E 6S4 Canada



Mobile: 215 896 3392



Email: [email protected]

Telephone: 780 989 6705 Mobile: 780 493 1706 Email: [email protected] Web: www.akshayabio.com



Web: www.akshayabio.com

Akshaya Bio Inc.

…..…………..focus is on vaccines

14

Akshaya Bio Inc.

Thank You…….

Akshaya Bio Inc.

…..…………..focus is on vaccines

15

View more...

Comments

Copyright � 2017 NANOPDF Inc.
SUPPORT NANOPDF